How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone?

Cancer Letters

Volumn 123, Issue 2, 1998, Pages 147-151

  Taubert, Helge ^a   Berger, Dieter ^a   Hinze, Raoul ^a   Meye, Axel ^a   Würl, Peter ^a   Hogendoorn, Pancras C W ^b   Holzhausen, Hans Jürgen ^a   Schmidt, Hannelore ^a   Rath, Friedrich Wilhelm ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Malignant fibrous histiocytoma of the bone; Mutational analysis; p16; p53; Tumor suppressor genes

Indexed keywords

PROTEIN P16; PROTEIN P53;

ARTICLE; BONE CANCER; CARCINOGENESIS; CLINICAL ARTICLE; DNA POLYMORPHISM; GENE MUTATION; HUMAN; HUMAN TISSUE; MALIGNANT FIBROUS HISTIOCYTOMA; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BONE NEOPLASMS; DNA, NEOPLASM; GENES, P16; GENES, P53; HISTIOCYTOMA, BENIGN FIBROUS; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0032579198     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00423-0     Document Type: Article

References (45)

1. Andreassen A., Oyjord T., Hovig E., Holm R., Florenes V.A., Nesland J.M., Myklebost O., Hoie J., Bruland O.S., Borresen A.L., Fodstad O. p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 53:1993;468-471.
2. Brachman D.G., Hallahan D.E., Beckett M.A., Yandell D.W., Weichselbaum R.R. p53 gene mutations and abnormal retinoblastoma protein in radiation-induced human sarcomas. Cancer Res. 51:1991;6393-6396.
3. Castresana J.S., Rubio M.P., Gomez L., Kreicbergs A., Zetterberg A., Barrios C. Detection of TP53 gene mutations in human sarcomas. Eur. J. Cancer. 31A:1995;735-738.
4. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
5. Feldman F., Norman D. Intra- and extraosseous malignant histiocytoma (malignant fibrous xanthoma). Radiology. 104:1972;497-508.
6. Fuchs N., Winkler K. Osteosarcoma. Curr. Opin. Oncol. 5:1993;667-671.
7. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
8. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., Harris C.C., Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25:1997;151-157.
9. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutation in human cancers. Science. 253:1991;49-53.
10. Hovig E., Andreassen A., Fangan B.M., Borresen A.L. A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas. Cancer Genet. Cytogenet. 64:1992;178-182.
11. Huvos A.G., Woodard H.Q., Heilweil M. Postradiation malignant fibrous histiocytoma of bone. Am. J. Surg. Pathol. 10:1986;9-18.
12. Iavarone A., Matthay K.K., Steinkirchner T.M., Israel M.A. Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proc. Natl. Acad. Sci. USA. 89:1992;4207-4209.
13. Iolascon A., Faienza M.F., Coppola B., Rosolen A., Basso G., Della-Ragione F., Schettini F. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Gen. Chrom. Cancer. 15:1996;217-222.
14. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S., Johnson B.E., Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
15. Kamb A., Shattuck-Eidens D., Eeles R., Liu Q., Gruis N.A., Ding W., Hussey C., Tran T., Miki Y., Weaver-Feldhaus J., McClure M., Aitken J.F., Anderson D.E., Bergman W., Frants R., Goldgar D.E., Green A., MacLennan R., Martin N.G., Meyer L.J., Youl P., Zone J.J., Skolnick M.H., Cannon-Albright L.A. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8:1994;22-26.
16. Katenkamp D., Stiller D. Malignant fibrous histiocytoma of bone. Virchows Arch. (B). 391:1981;323-335.
17. Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263.
18. Latres E., Drobnjak M., Pollack D., Oliva M.R., Ramos M., Karpeh M., Woodruff J.M., Cordon-Cardo C. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am. J. Pathol. 145:1994;345-355.
19. Leach F.S., Tokino T., Meltzer P., Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53:1993;2231-2234.
20. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
21. Levine A.J., Momand J., Finlay C.A. The p53 tumor suppressor gene. Nature. 351:1991;453-456.
22. Liu Q., Neuhausen S., McClure M., Frye C., Weaver-Feldhaus J., Grui N.A., Eddington K., Allalunis-Turner M.J., Skolnick M.H., Fujimura F.K., Kamb A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene. 10:1995;1061-1067.
23. Mashiyama S., Murakami Y., Yoshimoto T., Sekiya T., Hayashi K. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of PCR products. Oncogene. 6:1991;1313-1318.
24. Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol. 7:1987;961-963.
25. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D. 5′-CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:1995;686-692.
26. A. Meye, H. Taubert, P. Würl, R. Hinze, D. Berger, M. Bache, H. Schmidt, F.-W. Rath, No p16/CDKN2/MTS1 mutations independent of p53 status in soft tissue sarcomas, J. Pathol. (1997), in press.
27. Miller C., Mohandas T., Wolf D., Procimer M., Rotter V., Koeffler H.P. Human p53 gene localized to short arm of chromosome 17. Nature. 319:1986;783-784.
28. Miller C.W., Aslo A., Campbell M.J., Kawamata N., Lampkin B.C., Koeffler H.P. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet. Cytogenet. 86:1996;136-142.
29. Miller C.W., Aslo A., Won A., Tan M., Lampkin B., Koeffler H.P. Alterations of the p53, Rb, and Mdm2 genes in osteosarcoma. J. Cancer Res. Clin. Oncol. 122:1996;559-565.
30. Mousses S., McAuley L., Bell R.S., Kandel R., Andrulis I.L. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod. Pathol. 9:1996;1-6.
31. Mulligan L.M., Matlashewski G.J., Scrable H.J., Cavenee W.K. Mechanisms of p53 loss in human sarcomas. Proc. Natl. Acad. Sci. USA. 87:1990;5863-5867.
32. Naka T., Fukuda T., Shinohara N., Iwamoto Y., Sugioka Y., Tsuneyoshi M. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. Cancer. 76:1995;972-984.
33. Naumann M., Savitskaia N., Eilert C., Schramm A., Kalthoff H., Schmiegel W. Codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology. 110:1995;1215-1224.
34. Okamoto A., Demetrick D.J., Spillare E., Hagiwara K., Hussain P., Bennett W.P., Forrester K., Gerwin B., Serrano M., Beach D., Harris C.C. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA. 91:1994;11045-11049.
35. Reid A.H., Tsai M.S., Venzon D.J., Wright C.F., Lack E.E., O'Leary T.J. MDM2 amplification, p53 mutation, and accumulation of the p53 gene product in malignant fibrous histiocytoma. Diagn. Mol. Pathol. 5:1996;65-73.
36. Schneider-Stock R., Radig K., Roessner A. Loss of heterozygosity on chromosome 9p21 (p16 gene) uncommon in soft-tissue sarcomas. Mol. Carcinogen. 18:1997;63-65.
37. Serrano M., Hannon G.J., Beach D.A. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
38. Serrano M., Lee H.-W., Chin L., Cordon-Cardo C., Beach D., DeOinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 85:1996;27-37.
39. Smith-Sorensen B., Gebhardt M.C., Kloen P., McIntyre J., Aguilar F., Cerutti P., Borresen A.L. Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum. Mutat. 2:1993;274-285.
40. Stratton M.R., Moss S., Warren W., Patterson H., Clark J., Fisher C., Fletcher C.D., Ball A., Thomas M., Gusterson B.A., Cooper C.S. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene. 5:1990;1297-1301.
41. Taubert H., Meye A., Würl P. Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res. 56:1996;4134-4136.
42. Taubert H., Würl P., Meye A., Berger D., Thamm B., Neumann K., Hinze R., Schmidt H., Rath F.-W. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer. 7:1995;1187-1196.
43. Toguchida J., Yamaguchi T., Ritchie B., Beauchamp R.L., Dayton S.H., Herrera G.E., Yamamuro T., Kotoura Y., Sasaki M.S., Little J.B., Weichselbaum R.R., Ishizaki K., Yandell D.W. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 52:1992;6194-6199.
44. Wadayama B., Toguchida J., Yamaguchi T., Sasaki M.S., Kotoura Y., Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br. J. Cancer. 68:1993;1134-1139.
45. D.K. Wright, M.M. Manos, Sample preparation from paraffin embedded tissue, in: M.A. Innis, D.H. Gelfand, J.J. Sninsky, T.J. White (Eds.), PCR Protocols: A Guide to Methods and Applications, Academic Press, San Diego, CA, 1990, pp. 153-158.